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Objective: Sulfur mustard (SM) is one of the major potent chemical warfare and attractive weapons for terrorists. It
has caused deaths to hundreds of thousands of victims in World War I and more recently during the Iran-Iraq war
(1980–1988). It has ability to develop severe acute and chronic damage to the respiratory tract, eyes and skin.
Understanding the acute and chronic biologic consequences of SM exposure may be quite essential for developing
efficient prophylactic/therapeutic measures. One of the systems majorly affected by SM is the respiratory tract that
numerous clinical studies have detailed processes of injury, diagnosis and treatments of lung. The low mortality rate
has been contributed to high prevalence of victims and high lifetime morbidity burden. However, there are no
curative modalities available in such patients. In this review, we collected and discussed the related articles on the
preventive and therapeutic approaches to SM-induced respiratory injury and summarized what is currently known
about the management and therapeutic strategies of acute and long-term consequences of SM lung injuries.
Method: This review was done by reviewing all papers found by searching following key words sulfur mustard;
lung; chronic; acute; COPD; treatment.
Results: Mustard lung has an ongoing pathological process and is active disorder even years after exposure to SM.
Different drug classes have been studied, nevertheless there are no curative modalities for mustard lung.
Conclusion: Complementary studies on one hand regarding pharmacokinetic of drugs and molecular
investigations are mandatory to obtain more effective treatments.
Keywords: Sulfur mustard, Lung, Chronic, Acute, COPD, TreatmentBackground
A biofunctional mustard agent i.e., sulfur mustard, bis(2-
chloroethyl) sulfide (SM), was used in several conflicts
since the first World War and has caused more than
80% of all documented chemical war gas casualties [1-3].
It is well known that chemical agents have been used
against military personnel during conventional warfare,
however, due to the increasing threat of terrorist activ-
ities, the focus has now broadened to encompass the
threat posed to civilians. It maintains to be a major
threat for use in battlefields and terrorist activities
against either military and civilian targets [4]. It has been
estimated that more than 100,000 Iranians were exposed* Correspondence: m.ghanei@bmsu.ac.ir
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reproduction in any medium, provided the orto chemical warfare agents during the 8-year Iraq-Iran
war, and around 50,000 mustard gas-affected individuals
are suffering from of chronic respiratory, eye and/or der-
matological complications [5]. Most victims (approxi-
mately 30,000) have been manifested different degree of
long-term lung injuries [6]. Ever since, SM has been
remained as a potent military and civilian threat [7], thus
efficient prophylactic/therapeutic measures of acute and
chronic pulmonary complications may be the most im-
portant challenge and intriguing goal in these setting.
Most of acute lung injury survivors are confined to the
upper respiratory tract (pharyngeal, palatal, tracheal
lesions) and/or lower respiratory tract that had caused
to fatal consequences due to airways complications [8].
Over many years, several surveys on long-term effects of
SM, were published on lower respiratory tract system
that revealed most frequent long-term respiratory effectsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Poursaleh et al. DARU Journal of Pharmaceutical Sciences 2012, 20:27 Page 2 of 11
http://www.darujps.com/content/20/1/27were including bronchiolitis obliterans (BO), chronic
bronchitis, bronchiectasis and hyper reactive airway dis-
ease [5,9].
Initially, medical groups supposed that they were
encountered to a simple and known respiratory disease,
so diagnostic and treatment lines were followed by the
existing methods for well known respiratory illnesses
like as asthma or chronic obstructive pulmonary disease
(COPD). After a while, owing to failure of the conven-
tional remedies, less of improving illnesses and resump-
tion of crippling symptoms and signs gradually have
revealed different aspects of these disorders. For ex-
ample, it is has been established that smoking is the
most important factor causing COPD and the adverse
effects are either dependent to dose and duration of ex-
posure. Fortunately, smoking cessation improves the
accelerated decline in forced expiratory volume in one
second (FEV1) in COPD [10]. In other words, even in
severe COPD smoking cessation slows the accelerated
rate of lung function decline and improves survival com-
pared with continued smoking [11]. But featuring differ-
ent scenarios, mustard lung injury was developed after
single exposure and was independent of dosage and has
progressive course. Because of the nature of SM-induced
lung injuries, term of “Disorder” has been used instead
of “Disease”. Ghanei and colleagues named this disorder
as “mustard lung” for the first time to emphasis on spe-
cific character of this entity [12].
More previous studies showed that BO has been
known to be the main pathological features of lung
lesions in mustard lung on the basis of the radiological,
histological, spirometric and laboratory findings [13].
Despite initial assumption, comprehensive investigations
confirmed that these patients do from experience either
pulmonary fibrosis or pulmonary emphysema [14-16].
According to the indicated differences in the patho-
genesis of COPD and mustard lung, different therapeutic
approaches have been considered for these patients [17].
Considering this fact whereas there is no cure for mus-
tard lung injury, the main strategy of treatment is to pre-
vent injuries by an effective protection and if occurred,
prevention of disease progression rather than curing
them or treating their symptoms. Consequently, we
reviewed all modalities by considering preventive
approaches; primary prevention (methods to avoid oc-
currence of disease), secondary prevention (methods to
diagnose and treat extant disease in early stages before it
causes significant morbidity) and tertiary prevention
(methods to reduce negative impact of extant disease by
restoring function and reducing disease-related compli-
cations) like as pulmonary rehabilitation.
This review could assist the clinicians and researchers
to efficiently target their studies in the field of thera-
peutic approaches to SM-induced pulmonary injury.Methods
All published studies concerning treatment of respira-
tory effects of SM were included until 2012 February.
Publications will be identified from the following elec-
tronic databases: Medline/Pubmed, Scopus, Google
Scholar, Embase, ISI Web of Knowledge, Biological
Abstracts and Chemical Abstracts. To include all of
studies in electronic databases, keywords such as sulfur
mustard; lung; chronic; acute; COPD; treatment were
used. Subsequently, the therapeutic approaches to SM-
induced pulmonary injury have been analyzed. In this
study, efficient prophylactic/therapeutic measures are
classified as acute and long-term SM-induced pulmonary
effects and in three categories of primary, secondary and
tertiary prevention.
Acute SM-induced pulmonary effects
After minutes to several hours of exposure to SM, cas-
ualties experience tracheobronchitis with hoarseness,
hacking cough, dyspnea, chest pressure, sore throat due
to edema and erythema of the pharynx and bronchial
tree [18,19]. During the next 12 hours, the main object-
ive clinical findings develop with increasing cough, tach-
ypnea, sinus pain [20,21]. Bronchiolar obstruction vs.
bronchospasm can be anticipated due to pseudomem-
brane formation within the airways, sloughing of epithe-
lium, and lower airway obstruction. After 24 to 48
hours, severe exposures cause to hemorrhagic pulmon-
ary edema, secondary pneumonia, and respiratory failure
due to necrosis with high mortality [20]. In spirometric
findings, more obstructive patterns than restriction have
been shown (53% vs. 2%) [19]. Generally, abnormal
pulmonary function tests and particularly restrictive pat-
terns tend to worsen over time [21].
Medical management of acute toxic effects of SM
Primary prevention
Primary prevention is the prevention of the disease in
susceptible individuals through promotion of healthcare
and specific protection. The goal of primary prevention
is to decrease the number of new cases (incidence) of a
disorder. The ability to rapidly detect, identify and moni-
tor chemical warfare agents is imperative for the efficient
use of both military and civilian defence resources. This
knowledge allows the severity and extent of a hazard to
be assessed so that areas that are clean or contaminated
can be identified. Furthermore, the information acquired
by these systems provides advice to military comman-
ders and first responders, regarding the donning of
individual protective equipment, sampling, handling,
analysis procedures and medical countermeasures. At
this stage, early diagnosis of attack or exposure and de-
contamination play a major role [22]. After exposure to
SM vapor, first-aid measures triage and medical
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ordered antidotal treatment with 1–500 mg sodium thio-
sulphate per kilogram body weight immediately [23-25].
In general treatment, control of pain and sedation of
the severely intoxicated patients may be required. Also,
supportive care of the patients is very important in their
management. Willems and his colleague have reported
that the application of extracorporeal detoxification pro-
cedures, such as haemoperfusion and haemodialysis,
have no definitely therapeutic or clinical effect, because
active mustard has not been identified in blood taken
from victims. Also, these procedures are not safe and
may facilitate coagulation disorders and systemic infec-
tions in such immunocompromised patients [23,26].
At acute phase, radiological evidence could be nor-
mal despite clinical signs e.g. bronchial rale, wheezing
and crackels but it is the best time to start therapeutic
interventions. Patients with acute SM lung injuries
often receive bronchodilators, corticosteroids, immuno-
suppressive agents, antibiotics, mucolytics, oxygen ther-
apy, and physiotherapy according to the involved
complication(s) [22,27,28]. Combination a number of
other drugs such as cysteine, sodium citrate, pro-
methazine, heparin may be effective for the raising
their protective activity against SM lung injuries. Also,
Vitamin E could be used in combination with corticos-
teroids for protection against chemical-induced lung
injury. [27-30]. But these different treatments still have
no optimal effectiveness and also have known adverse
effects in this stage of disease.
L-NAME & L-TC: L-nitroarginine methyl ester (L-
NAME) and L-thiocitrullline (L-TC) are applied as two
effective and protective drugs against the acute toxicity
of SM. Maximal protective effects of L-NAME are
delayed up to 3 h post-SM exposure that were
dependent on the continued presence of L-NAME in
the medium and were persistent up to 48 h after SM
exposure [31,32]. Conversely, the protection conferred
by L-TC against SM was persistent, and did not require
the continued presence of L-TC after the initial SM le-
sion was expressed [33-35]. Some studies have been
carried out for treatment of lung effects of SM-exposed
patients in vivo and in vitro are summarized in Tables 1
and 2.
Long-term SM-induced pulmonary adverse effects
After acute phases, respiratory problems are the greatest
cause of long-term disability among people with combat
exposure to mustard gas [17]. Long-term mustard lung
injuries include chronic bronchitis (59%), tracheobron-
chial stenosis (24%) (ranging from diffuse involvement
to isolated glottic or subglottic stenosis), asthma (11%),
bronchiectasis (9%), airway narrowing due to scarring
(10%), rarely honeycomb lung pathology as like fibrosis,and slightly increased incidence of lung cancer after a la-
tency of 20 years and more [6,57].
Previous cohort studies have shown underlying pul-
monary diseases such as resistant asthma and cigarette
smoking can change the structure of the small airways
and cause irreversible airflow obstruction. Thus they
may be interfered with diagnostic and therapeutic pro-
cesses of mustard lung by causing similar clinical fea-
tures [23]. Conversely, comorbidity of resistant asthma
and/or cigarette smoking with mustard lung may delay
common therapeutic responses of mustard lung.
Several investigations have been evaluated long-term
markers of SM toxicity 20 years after exposure. Pourfar-
zam and colleagues well assigned the association of the
serum levels of IL-8, IL-6, C-reactive protein (CRP) and
RF with long-term pulmonary involvement. It was con-
cluded that serum levels of these inflammatory media-
tors probably do not play a major role in pathogenesis
and persistence of pulmonary complications and could
not reflect the degree of severity of pulmonary involve-
ment following SM exposure [14,58]. Also, numerous
studies have documented the theory of considering the
oxidative–antioxidative imbalance and dependent mar-
kers of pulmonary inflammation in the pathophysiology
of SM-induced pulmonary lesion. For example, Shohrati
et al. showed Patients with moderate-to-severe SM-
induced lung injuries had a tendency to show decreased
level of glutathione and increased level of malondialde-
hyde (MDA) rather than those with mild injuries [59].
Latest data also show that mutations in the tumor sup-
pressor gene, p53 may increase incidence of early-onset
lung cancer in SM-exposed injury patients [57]. On the
other hand, recently various studies have been described
associated pathologic sequela of SM poisoning. Tracheo-
bronchomalacia (TBM) and air trapping caused by
affecting small and large airways are often observed in
high-resolution computerized tomography (HRCT)
scans of the chest of mustard gas exposed patients prov-
ing significant airway disease including constrictive (ob-
literative) bronchiolitis. However, the process is different
from BO resulted from lung transplantation [14,60].
There are some data which support the role of oxi-
dative stress and apoptosis as two prominent mecha-
nisms that are involved in pathogenesis of mustard
lung [13,61].
Secondary prevention
Treatment of long-term toxic effects Secondary pre-
vention focuses on identifying and treating people with
established disease. In secondary prevention, the goal is
to lower the rate of established cases of the disorder in
the population (prevalence). It is relevant that the thera-
peutic response of long-term pulmonary complications
Table 1 Treatment of lung effects of SM-exposed patients in vitro
Reference Authors, Year, Country Design of study/Intervention(s) Participants Result/s
[27] Wigenstam et al. 2009, Sweden Dexamethasone
liposome-encapsuled vitamin E
Mouse Effective
[30] Hoesel et al. 2008,USA Alpha/gamma-tocopherol Rat Effective
NAC+ alpha/gamma-tocopherol
[35] Sawyer et al. 1998. Canada L-thiocitrulline Chick embryo Effective
[31] Sawyer 1998. Canada L-NAME Chick embryo Effective
[36] Paromov et al. 2008,USA NAC Intercellular
macrophages
Effective
[37] Atkins et al. 2000,USA NAC Endothelial cells Effective




[39] Anderson et al. 2000,USA NIA Rat Ineffective
NAC Effective





[41] Guignabert et al. 2005. USA Doxycycline Guinea pigs Effective






[43] Raza et al. 2006, USA Doxycycline Human lung
epithelial cells
Effective
[44] Anderson et al. 2009 Aprotinin Rat Effective
[45] Yourick et al. 1992 NIA Guinea pigs Ineffective
[46] Wilde and Upshall. 1991 Esters of cysteine Rat Effective
[47] Zboril et al. 2012 zero-valent iron nanoparticles
ferrate(VI)/(III) composite
Invitro Effective
[48] Boskabady et al. 2011 Nigella sativa Guinea pigs Effective
Nigella sativa + dexamethasone
[49] O’Neill et al. 2010 AEOL 10150 Rat Effective
*Niacinamide (NIA),N-acetyl cysteine (NAC), L-nitroarginine methyl ester (L-NAME), Aeolus(AEOL-10150) a small-molecule antioxidant analogous to the catalytic site
of superoxide dismutase, Butylated hydroxytoluene (BHT).
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one person to another due to various internal factors
(i.e., healthy status, underlying disease, and genetic ten-
dency) and external factors (i.e., toxicities, duration and
frequency of exposure, co-exposure, emergent and
follow-up medical care, smoking, and synergistic effect
of occupational exposure).
Corticosteroids Inhaled corticosteroids (ICS) are widely
used in the treatment of patients with COPD but still
their effectiveness in COPD remains controversial
[20,62,63]. Inflammatory cells accumulation in the re-
spiratory tract and production of inflammatory media-
tors can be correlated directly with altered lung function
in SM-induced lung injury suggests that steroids depend
on the extent of lung injury play a key role in treatment
[64]. Furthermore, corticosteroids are extensively used
to resolve exacerbation of respiratory symptoms inmustard lung. It should be considered that since mus-
tard lung disorder is contributed to higher morbidities
rather than mortalities, maintenance prescription of oral
corticosteroids just may increases the related complica-
tions and has no effect on patients’ survival. Therefore,
although ICS are significantly helpful in this setting, long
term oral corticosteroids consumption should be war-
ranted considered for severe cases [65].
However, this point is important with regard to differ-
ent etiologies that lack active inflammation in these
patients. The serum levels of these inflammatory media-
tors probably do not have any major role in pathogenesis
and persistence of pulmonary complications and cannot
reflect the degree of severity of pulmonary involvement
following SM exposure [14]. Also, ineffectiveness of cor-
ticosteroids in airway reversibility in more than 50% of
mustard injured cases [20] may imply the absence of ac-
tive eosinophilic inflammation in these patients.
Table 2 Treatment of lung effects of SM-exposed patients in vivo
Reference Authors, Year, Country Design of study/Intervention(s) Participants Result/s
[20] Ghanei et al. 2005, Iran Group 1: Oral prednisolone 65 mustard gas-exposed chronic
bronchitis patients





[50] Ghanei et al. 2004, Iran Clarithromycin + Acetylcysteine mustard gas-exposed patients17 Effective
[51] Ghanei et al. 2008, Iran Group 1: NAC 144mustard gas-exposed patients with
normal pulmonary function test
Effective
Group 2: Placebo (Group 1:72 & Group 2:72) Ineffective
[52] Shohrati et al. 2008, Iran Group 1: NAC 144mustard gas-exposed patients with
impaired pulmonary function test
Effective
Group 2: Placebo (Group 1:72 & Group 2:72) Ineffective
[53] Boskabady et al. 2008, Iran Group 1: PC(20) salbutamol 22 exposed to chemical warfare
(Group 1:11 & Group 2:15)
Effective
Group 2: PC(35) salbutamol 15 normal control Ineffective
[54] Ghanei et al. 2007, Iran Group 1: Fluticasone
Propionate and Salmetrol
105 participants warfare
(Group 1:52 & Group 2:53)
More effective
Group 2: Beclomethasone and
Salbutamol Inhaler
Less effective
[55] Panahi et al. 2006, Iran Group 1: Interferon
Gamma-1b + Prednisolone
36 exposed to chemical warfare





[56] Ghanei et al. 2010, Iran Air: Oxygen 24mustard gas-exposed patients Less effective
Helium: Oxygen More effective
*N-acetyl cysteine (NAC).
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used as a protective agent that enhance glutathione-
S-transferase (GSH) synthesis, as well as prevent oxi-
dative activation of NF-кB inducing endothelial cell
death and generate a local inflammatory reaction asso-
ciated with the release of endothelial-derived cytokines
[50,66,67]. Stav et al. have expressed a beneficial effect
of NAC on physical performance probably due to a re-
duction in air trapping in stable, moderate-to-severe
COPD [68].
To date it is identified that SM or its analogs reacts
with nucleic acids, proteins, lipids and small molecular
weight metabolites such as glutathione and lead to oxi-
dative stress. It can increase oxidative products include
reactive oxygen species (ROS), lipid peroxidation pro-
ducts and oxidized proteins, and inhibits antioxidant
enzymes such as superoxide dismutase, catalase, GSH,
and thioredoxin reductase. This inequity by SM can
damage pulmonary matrix cells and disrupt cellular
redox homeostasis [29,36,37]. Mehrani et al. was also
showed that S100 calcium-binding protein A8 and Apo
A1 both increased in BAL fluid in endotoxin-challenged
in patients with high severity of SM exposure [69]. Nu-
merous investigations have suggested an anti-oxidant ef-
fect for these two proteins [70,71], which confirm theoxidative–antioxidative imbalance in the pathophysi-
ology of SM-induced pulmonary lesion.
As a result, successful therapy for SM toxicity may de-
pend on the development of new antioxidants effective
against SM-induced ROS and their improved delivery to
target tissues. Also, a previous study showed that SM
causes a transient decrease in inducible nitric oxide syn-
thase (iNOS) protein syntheses rather than a direct in-
hibition of iNOS activity due to covalent modifications
by SM [72]. In such setting where oxidative stress is an
ongoing and long term process, using antioxidative mo-
dalities should be started soon in early stage of disease
to maintain oxidant-antioxidant balance and continued
as long as the underlying pathology is persisting.
The NAC would prevent GSH depletion and restore
the loss of iNOS activity in stimulated macrophages and
in rat model it could protect bronchial epithelial cells
against SM in vitro [36,37]. In addition, NAC can reduce
the level of tumor necrosis factor-α (TNFα) in lung
transplanted persons [38,73]. It also reduces the secre-
tion of many inflammatory modulators and could pre-
vent thickening of respiratory airways and bronchial
smooth muscle hypertrophy. Therefore NAC not only
can be used in treating bronchitis and bronchiolitis, but
also prevent mustard induced pulmonary lesions due to
Poursaleh et al. DARU Journal of Pharmaceutical Sciences 2012, 20:27 Page 6 of 11
http://www.darujps.com/content/20/1/27oxidative stress. An in vivo study has been showed NAC
vs. niacinamide (NIA) has more effective against SM-
induced lung injury that determined by biomedical and
cytological analysis of lavage fluid [39]. In a double-blind
clinical trial study on 144 SM-induced BO patients with
normal PFT improved dyspnea, wake-up dyspnea and
cough after 4 months of NAC administration compared
with the placebo group. NAC reduced sputum from
76.9% of cases before the trial to 9.6% of cases after
the trial. Spirometric components were significantly
improved in NAC group compared with the placebo
group [51]. Also, in another double-blind clinical trial
study on mustard gas-exposed patients with impaired
pulmonary function test, clinical-conditions and spiro-
metric findings in these patients can improve after
fourth months administration of NAC [52].
Some different studies have been carried out based on
antioxidant properties for treatment of respiratory ad-
verse effects of SM-exposed patients in vivo and in vitro.Bronchodilators Bronchodilators can be applied in
patients with increased airway hyper-reactivity and espe-
cially for moderate to severe cases with SM exposed
lung injuries [72]. Combination of β-agonist (e.g., salbu-
tamol) and an anticholinergic (e.g., ipratropium brom-
ide) has been found to be more effective than any of
other bronchodilators used alone in these patients [53].
A study has shown combination therapy with long-
acting beta 2-agonists and inhaled corticosteroids for
12 weeks. In addition, short-term intravenous pulse or
oral corticosteroid therapy can improve FEV1, FVC and
PEF of patients with mustard gas-induced chronic bron-
chitis in the case of exacerbation, and this effect is syner-
gistic with inhaled β -2 agonist bronchodilators [54].Macrolides It has been proven that macrolide antibio-
tics may serve as potential vesicant respiratory therapeu-
tics. Macrolides are effective in reducing SM-induced
overproduction of proinflammatory cytokines and med-
iators, as well as improving the degenerated chemotactic
and phagocytotic functions of monocytes following SM
exposure. Also, macrolide antibiotics may lead to clear-
ance improvement of apoptotic material in the airway
and ultimately cause to reduce airway inflammation due
to SM inhalation [40,74]. Specifically, mustard lung
patients are observed to have severe and persistent re-
spiratory symptoms in the absence of eosinophilic in-
flammation. In other word non-eosinophilic (neutrophil
mediated) inflammation is relatively common. This
would have major consequences for the treatment and
prevention since most previous treatment and preven-
tion strategies were almost entirely focused on allergic
and eosinophilic measures. In such a non-eosinophilicinflammation the macrolides are one of best candidate
to play their anti-inflammatory role.
We should emphasize that previous studies showed to
excess neutrophil in BAL studies [15], to decrease the
circulating levels of IL-6, IL-8, CPR, RF in SM exposed
patients with various degrees of late pulmonary compli-
cations [13,14] and to increase expression of markers of
inflammation including cyclooxygenase-2 (COX-2),
TNFα, iNOS, matrix metalloproteinase-9 (MMP-9) and
a significant increase in total protein, IL-1/ and IL-13
that each of which has been implicated in pulmonary
toxicity on SM exposed model [16,25]. But, other sur-
veys have been noted that there is no active inflamma-
tion in these patients because corticosteroids are
ineffectiveness in airway reversibility in more than 50%
of mustard injured cases [20]. In other words, the effi-
cacy of inflammation mechanisms is really unobvious in
pathogenesis pulmonary complications and does not re-
flect the degree of severity of pulmonary involvement
following SM exposure [14].
Evaluation and treatment of gastroesophageal reflux
disease (GERD)
Studies of patients with chronic upper airway symptoms
describe a potential relationship between GERD and
upper airway conditions. The hypothetical mechanisms
linking upper respiratory symptoms with GERD include
heightened bronchial reactivity, microaspiration, and a
vagally mediated reflex mechanism [75]. However, in the
case of GERD-related respiratory symptoms the typical
digestive syndrome is frequently absent, the situation
corresponding to the so-called ‘silent GERD’ [76]. The
relationship of upper respiratory symptoms and GERD is
based upon investigations of subjects with persistent
upper respiratory symptoms. In the majority of these
cases, GERD was asymptomatic or the symptoms were
not sufficiently severe to warrant an evaluation of GERD
before the evaluation of upper respiratory symptoms
[77]. Treatment of GERD could result in marked im-
provement or even disappearance of symptoms in
patients with chronic respiratory symptoms. In addition
in the specific situation of GERD-related respiratory pro-
blems, empirical therapy with proton pomp inhibitors
(PPI) is frequently proposed in these cases [76].
Some studies addressed the correlation between re-
spiratory symptoms in mustard lung disorder and GERD
symptoms [77]. In a study by evaluating of chronic
cough in mustard lung patients GERD was accounted
for 44% of chronic cough of the patients [78]. Evalu-
ation of GERD and treatment or even empirical therapy
with a PPI especially in symptomatic and uncontrolled
respiratory symptoms is highly recommended in mus-
tard lung to relief of respiratory symptoms associated
with GERD.
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for proteases such as serine, cysteine, and MMP in the
pathogenesis of SM-induced damage, even in the SM
exposed model [21,44]. SM inhalation may cause cell
death of airway macrophages by themselves, as well as
degenerated chemotactic and phagocytic functions of
the surviving cells. As a result, as hallmarks of SM inhal-
ation exposure, these consequences may affect incompe-
tent clearance of dead cells, and accumulation of
apoptotic and necrotic fragments promoting the ongoing
inflammation and losing of structural integrity in the air-
way. These processes were caused to damage normal
pulmonary parenchyma and regard to emphysema. Ab-
sence of emphysema in nonsmoker SM-induced lung in-
jury is against over activity proteolytic molecules in
these patients.
Previous studies reported treatment with aprotinin
and to a lesser extent ilomastat, as well as doxycycline
reduce some of the direct inflammatory response and
damage associated with SM-induced lung injury [79].
Aprotinin irreversibly binds to proteases that contain a
serine amino acid residue in their catalytic site inhibiting
the actions of trypsin, plasmin, kallikrien, elastase, uro-
kinase, and thrombin in an increasing dose-dependent
manner, respectively [80].
Doxycycline also exhibits non-specific MMP inhibitory
activity such as MMP-2, MMP-9 and cellularity and pro-
tein levels. In addition, doxycycline and related tetracy-
clines can be influence on iNOS expression and nitric
oxide production, to reduce inflammatory cytokine re-
lease, and to scavenge reactive oxygen species [41,43,65].
∝1-antitrypsin activity (AAT) Previous studies showed
that AAT due to oxidative stress has been diminished
after exposure to SM. But significant difference in PI
phenotype and the effect of SM on the mutation of the
AAT gene is unlikely. Additionally, it could be concluded
that just a single exposure to SM has no effect on chan-
ging the phenotype of AAT [81]. AAT deficiency has no
cure. Thus, people who have AAT deficiency and mod-
erate to severe impairment of pulmonary function due
to long time exposure to SM could be continued med-
ical care and lifestyle changes that help to manage their
health. Medical care may included inhaled bronchodila-
tors and inhaled steroids, protection with Flu and
pneumococcus vaccines, pulmonary rehabilitation, and if
needed, extra oxygen therapy.
Interferon gamma-1b (INF γ-1b) It has been recently
demonstrated that transforming growth factor β1 (TGF-b1)
target protein and plays a fundamental role in BO
pathogenesis and is substantially increased in BAL
aspirates and target tissues of SM exposed patients,
compared with non-exposed individuals. Also, TGF-βespecially TGF-β1 increase in SM- exposed patients.
This factor has been described to play an important role
in the pathogenesis of progressive inflammatory and fi-
brotic diseases such as IPF and BO [17]. Ghanei et al.,
reported that honey combing that is typical for pulmonary
fibrosis is not found in lung mustard and BO is main
complication of these patients [7]. In addition, current
treatments of BO in post-lung transplant patients i.e., im-
munosuppression and corticosteroid therapy, are not ef-
fective in SM exposed patients [18,19]. The IFN-γ1b is a
bioengineered form of interferon gamma, a protein that
acts as a biologic response modifier through stimulation
of the human immune system. We presume that the re-
sponse to treatment in our patients can be attributed to
the down regulating effects of IFN-γ1b on TGF-b1
[17,55,82]. Recently, it was shown that six-month treat-
ment with IFN-γ1b plus a low-dose prednisolone could
improve pulmonary function of SM-exposed patients with
severe delayed lung complications [55,82].
Surfactant therapy Recent studies on animal model
have also proposed surfactants in combination with
bronchodilators or anti-inflammatory agents. This medi-
cation may be useful in SM induced lung injury [16,42].
Angiotensin-converting enzyme (ACE) genotype ACE
genotype and the Renin Angiotensin system influence
the severity of the late respiratory complications of
mustard gas exposure with the D allele being asso-
ciated higher FEV 1% predicted. It is evidence that
ACE influences may open the way to new therapeutic
options [83].
Treatment during exacerbation
In a recent report has suggested that the use of heliume
oxygen mixtures with non-invasive ventilation can be
decreased airway resistance and work of breathing in
subjects with chronic dyspnea following SM exposure.
Therefore, helium oxygen mixtures usage may im-
prove impairment of function during exacerbation
and also pulmonary in moderate to severe chronic
lung effects [56].
Other therapies during exacerbation are short courses
of systemic corticosteroids or inhaled corticosteroids,
antibiotics, morphine, oxygen supplement therapy,
mucolytics and chest physiotherapy. However, the opti-
mal choice of antibiotic and length of use are still
unclear.
Tertiary prevention and rehabilitation
Tertiary prevention commonly includes the prevention
of the disease progression after it is clinically noticeable
and the diagnosis has been established. In fact it seeks to
stabilize or decrease the amount of disability associated
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term follow up that mortality is usually low in patients
with injuries of SM [84]. It leads to high prevalence of
victims and frequent end stage morbidities. In such cases
exercise rehabilitation shows significant results. Also
long Long-term supplemental oxygen therapy and nasal
intermittent positive pressure ventilation have been
prescribed.
It is of note that lung transplantation because they
have a long term survival. In addition there is no evi-
dence regarding possible effect(s) of underlying lung
pathology on post transplant lung tissue.
New therapeutic approach First, it is very important to
note that regarding to the pathogenesis of the disorder
(oxidant-antioxidant imbalance) in patients with injuries
of SM, we expect to patients response to the treatment
with anti oxidative agents [59]. Hence, every therapeutic
agent that can enhance cellular anti-oxidant supply may
be effective in such these patients. In our studies that
not published yet, we have been assessing new thera-
peutic approach as Curcumin, Hypertonic saline and
Manitol in SM injured patients.
Curcumin There are so many evidences which con-
firmed the efficacy of Curcumin as a herbal medication
on inflammation, antioxidant supply, neoplasm and on
the apoptotic pathway (such as NF-KB) [85,86]. Curcu-
min can affect the TGF-beta/Smads signaling pathway
and also can regulate inter-cellular adhering molecule
(such as Laminin and cathepsin that was presented as
one of the main mechanisms of SM injury [87-89].
There is some evidence that is confirmed the efficacy of
Curcumin on the response of airway epithelial cell to
toxic agents [90]. Therefore, it seems that it can be ef-
fective on control of severity of SM injury disorder al-
though the main problem in using this drug was the low
systemic availability because of the efficient first-pass
metabolism and some degree of intestinal metabolism
when administered via the oral [91]. If the efficient Lipo-
somal formula of Curcumin is produced can impres-
sively use as inhaled, oral or intra venous in SM injured.
Hypertonic saline (HTS) It is a sodium chloride solu-
tion with hyper osmolarity which used for septic shock,
bronchiolitis and sputum induction [92]. Nebulization
with HTS can regulate sodium transport across airway
lining [93]. Inhalation of HTS improve cilliary function
of epithelial cell in which can be useful in these patients
[94]. Nowadays, the effect of HTS on the inflammatory
cytokines such as IL-8 was demonstrated [12,95]. Nebu-
lization of HTS 5% was safely used [96] and can be su-
perior to current therapy for early treatment of SM
injured patient with Bronchiolitis obliterans.Mannitol Inhaled Mannitol have several effect on lung
like HTS such as regulating water flows into the airway
lumen via osmotic gradient modification and diluting
airways mucus and improving muco-ciliary function and
therefore could have a role in treating chronic suppura-
tive lung disease and resolution of airway inflammation
such as SM injured lung [97,98]. On the other hand, its
formulation as inhaler or nebulizer makes it easy to use
but headache as the most common adverse effect limited
the interest to use it.
Conclusion
Mustard lung has an ongoing pathological process and
is an active disorder even years after exposure to SM.
Although the previous researches were effectively used
biological or non-biological medications for SM injuried
lung [45-49], there are no curative modalities for mus-
tard lung. Therefore the main goal is primary prevention
and if injury had been occurred, secondary prevention
for victim should be considered. In disabled and end
stage victims some tertiary preventive method are avail-
able. Complementary studies on one hand regarding
pharmacokinetic of drugs and molecular investigations
to understand more about underlying physiopathology
of such a disorder, and on the other hand performing
more survey and controlled clinical trials are mandatory
to obtain more effective treatments.
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